At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Olaparibdrug
Likely dose
Olaparib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Olaparib for Ewing's Sarcoma. Completed, enrolled 12 participants across 3 sites.
Detailed Summary
This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEwing's Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartMay 2012
Primary CompletionJan 2014
Study CompletionNov 2014
TodayJul 2026
First PostedApr 24, 2012
Enrollment StartMay 1, 2012
Primary CompletionJan 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.2 years ago
Interventions
Olaparibdrug
400mg PO BID Continuous